| Name | Title | Contact Details |
|---|
Introducing QXO.
With headquarters in the greater St. Louis region, UNCOMN provides Industry-Leading B2B Management and Technology Consulting Services. We are a diverse group of engineers, architects, analysts, hackers, and geeks who thrive on finding elegant solutions to wickedly complex organizational, logistic, process, data, and technical problems. In everything we do, we pursue truth, goodness, and beauty. We put people first and hire for the long-term, not for the contract. We put the right people in the right roles. We work with rigor, transparency, and excellence – doing whatever it takes while upholding unquestionable integrity, from start to finish. And we do so with the intention of making our team, clients, and communities better along the way. At UNCOMN, we arent just about profits and the bottom line. We uphold service before self, giving over receiving and social impact over siloing. Its our duty as industry experts to lead by example, share what we know and help create strong, vibrant communities in which we are proud to live and serve. We invest in and mentor for SixThirty CYBER, a business development program that offers cyber security-based technology startups with up to $250,000 of services each year. Through these services, the St. Louis regions top executives and chief information security officers provide hands-on training, mentoring and network opportunities to the startups key stakeholders.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
HBT is a not-for-profit health and welfare trust that provides group health and welfare benefits on behalf of participating employers for nearly 265,000 eligible employees, their eligible dependents, and beneficiaries employed in health care and social services in British Columbia. The primary benefits provided by HBT are Group Life, Accidental Death & Dismemberment (AD&D), Weekly Indemnity, Long Term Disability (LTD), Extended Health, and Dental. HBT ensures these benefits are administered in accordance with provisions and plan design negotiated by HEABC, CSSEA, and single-site collective agreements.
CI Financial is an independent company offering global asset management and wealth management advisory services. We are driven by a commitment to provide individuals and institutions with the highest-quality investments and advice—and offer a comprehensive and innovative selection of strategies and services. Our employees are at the heart of everything we do. They must be comfortable in a fast-paced environment in an industry that is always changing. A healthy dose of ambition, a willingness to go the extra mile and a strong sense of camaraderie are what we look for in our team members.